MedTrace Logo

Imaging With [11C]Martinostat in Breast Cancer

NCT03721211 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-03-03

No results posted yet for this study

Summary

This research study is studying a PET imaging tracer as a possible means of imaging breast cancer.

The imaging agent involved in this study is:

-\[11C\]Martinostat (called C-eleven-Martinostat)

Conditions

Interventions

DRUG

[11C]Martinostat

a type of dye used for radiographic imaging of the HDAC protein

DEVICE

MR-PET scanner

PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs

Sponsors & Collaborators

  • Christine Elizabeth Edmonds

    lead OTHER

Principal Investigators

  • Christine E Edmond, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-02-28
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03721211 on ClinicalTrials.gov